<DOC>
	<DOC>NCT01956799</DOC>
	<brief_summary>The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.</brief_summary>
	<brief_title>Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1. Patients aged 18 and older 2. Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia 3. transfusiondependent anemia undergoing chelation therapy with deferasirox or deferoxamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>PMF</keyword>
	<keyword>CMML</keyword>
	<keyword>AA</keyword>
</DOC>